泌尿生殖系统癌症中的孢子-猫眼课题宝

泌尿生殖系统癌症中的孢子

批准号：

7289865

负责人：

COLIN P.N. DINNEY

金额：

$255.0万

依托单位：

UNIVERSITY OF TX MD ANDERSON CAN CTR

依托单位国家：

美国

项目类别：

财政年份：

2001

资助国家：

美国

项目状态：

已结题

起止时间：

2001-09-25 至 2011-08-31

来源：

https://reporter.nih.gov/project-details/7289865

关键词：

Achievement Address Adenoviruses Adverse effects Affect African American Alcohols Algorithms Angiogenesis Inhibitors Animal Model Animals Antibiotics Antibodies Apoptosis Apoptotic Appointment Area Arts Asians Awareness Back Behavior Therapy Behavioral Behavioral Sciences Bioinformatics Biological Biological Response Modifier Therapy Biology Biometry Biostatistics Core Bladder Bladder Neoplasm Bladder Tissue Bleomycin/Cytarabine/Methotrexate/Vincristine Blocking Antibodies Blood Blood Vessels Bortezomib Budgets Businesses CD-ROM CDKN2A gene Calmette-Guerin Bacillus Cancer Biology Cancer Center Cancer Center Support Grant Cancer Patient Candidate Disease Gene Cardiac Cardiovascular Diseases Cardiovascular system Caring Categories Cause of Death Cell Cycle Deregulation Cell Death Induction Cell Line Cell Proliferation Cells Cessation of life Cetuximab Chairperson Characteristics Charge Chemoprevention Chemopreventive Agent Chemotherapy-Oncologic Procedure Chinese People Chromosome Mapping Church Ciprofloxacin Cisplatin Cisplatin/Doxorubicin/Methotrexate/Vinblastine Cisplatin/Gemcitabine Class Clinic Clinical Clinical Data Clinical Research Clinical Trials Clinical Trials Design Coenzyme A Cognitive Cognitive Therapy Collaborations Collection Combination Chemotherapy Combined Modality Therapy Combined Pharmacological and Behavioral Treatment Commit Communities Community Outreach Complement Complex Consensus Core Facility County County Hospitals Coxibs Cutaneous Cyclin-Dependent Kinases Cystectomy Cytotoxic Chemotherapy Cytotoxic agent DNA Repair DNA analysis DNA biosynthesis DNA chemical synthesis Data Dependence Detection Development Diagnosis Discipline Disease Disease Progression Disease regression Disease remission Disorder by Site Division of Cancer Prevention Dose Doxorubicin Doxorubicin/Gemcitabine Doxorubicin/PS-341 Drug Combinations Drug Metabolic Detoxication EGFR inhibition Early Diagnosis Education Education and Outreach Effectiveness Epidemiologist Epidermal Growth Factor Epidermal Growth Factor Receptor Epithelial Esters Ethnic group Etiology Evaluation Event Exhibits Explosion Exposure to Faculty Family Figs - dietary Flow Cytometry Fluorouracil Focus Groups Formalin Funding Future Gefitinib Gelatinase B Gene Transfer Generations Genes Genetic Genetic Predisposition to Disease Genetic Processes Genetic Risk Genetically Engineered Mouse Genitourinary system Genomics Goals Grant Growth Growth Factor Head Head and Neck Cancer Health Health Personnel Health Professional Health behavior Heart Atrium Hispanics Histologic Histopathology Facility Hodgkin Disease Human Human Genome Hybridomas Ifosfamide In Vitro Incidence Indigent Individual Inflammation Inflammatory Informatics Inherited Institution Interdisciplinary Study Interferons Interleukin-1 Intervention Invasive Investigation Joints Knowledge LDL Cholesterol Lipoproteins Laboratories Laboratory Research Language Lead Life Expectancy Life Support Care Link Liposomes Literature Localized Disease Lymph Node Dissections Lymphoma M-VAC regimen Maintenance Malignant Neoplasms Malignant neoplasm of prostate Malignant neoplasm of urinary bladder Maps Measures Mediating Mediation Medical Oncologist Medical Surveillance Medicine Memorial Sloan-Kettering Cancer Center Mental Depression Metalloproteases Methodology Methylation Minority Mission Modeling Molecular Molecular Biology Molecular Epidemiology Molecular Profiling Monitor Morbidity - disease rate Multicenter Trials Mus Muscle Mutate Mutation Myofibroblast Natural History Nature Neoadjuvant Therapy New Agents Nicotine Nicotine Dependence Nucleotides Numbers Nursing Research Nylons Online Systems Operative Surgical Procedures Oral Administration Organ Outcome Oxidative Stress Oxidoreductase PTEN gene Paraffin Embedding Pathogenesis Pathologist Pathology Pathway interactions Patients Pelvis Personal Satisfaction Personality Persons Pharmaceutical Preparations Pharmacogenetics Phase Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phenotype Phosphorylation Physicians Physiological Planet Mars Platinum Population Population Heterogeneity Population Study Populations at Risk Postdoctoral Fellow Predisposition Preparation Prevention Principal Investigator Printing Prior Therapy Procedures Process Professional Education Prognostic Marker Program Description Program Research Project Grants Proliferating Prostate Proteasome Inhibition Proteasome Inhibitor Proteins Proteomics Protocols documentation Provider Psychiatry Psychophysiology Psychosocial Factor Purpose Qualifying Quality of life Questionnaires Quinolones RB1 gene Randomized Range Rate Recombinant DNA Recombinants Records Recruitment Activity Recurrence Refractory Relapse Relative (related person)Relative Risks Reporting Reproduction spores Research Research Personnel Research Priority Research Support Research Training Residual Neoplasm Resistance Resolution Resource Sharing Resources Retinoblastoma Genes Retinoblastoma Protein Retroperitoneal Space Risk Risk Assessment Role SCID Mice Sampling Schedule Science Scientist Screening for Prostate Cancer Screening procedure Seminal Series Serum Services Single Nucleotide Polymorphism Site Smoker Smoking Smoking Behavior Solid Sorting - Cell Movement Specimen Staging Standards of Weights and Measures Strategic Planning Stress Subgroup Supportive care Surveys Symptoms Systemic Therapy TNF gene TNFRSF5 gene TNFSF10 gene TP53 gene Taxane Compound Techniques Technology Testing Texas Therapeutic Therapeutic Intervention Time Tissue Microarray Tissue Procurements Tissue Sample Tissues Tobacco Tobacco Use Cessation Tobacco Use Disorder Tobacco use Tobacco-Associated Carcinogen Toxic effect Training Transgenic Model Transgenic Organisms Transitional Cell Carcinoma Translating Translational Research Transurethral Resection Treatment Protocols Triplet Multiple Birth Tumor Bank Tumor Suppressor Genes Tyrosine Kinase Inhibitor Uncertainty University of Texas M D Anderson Cancer Center Unresectable Update Upper arm Urine Urogenital Cancer Urologic Oncology Urologist Urology Urothelium Ursidae Family Vascular Endothelial Cell Vascular Endothelial Growth Factors Velcade Videotape Vinca Alkaloids Visceral Woman Work Xenograft procedure adenoviral-mediated anticancer research base bevacizumab biobehavior cancer cell cancer genetics cancer imaging cancer recurrence cancer therapy career celecoxib cellular imaging chemotherapy cohort combinatorial concept cyclooxygenase 2 cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisone protocol cytokine cytotoxic cytotoxicity data management day design disease natural history docetaxel expectation experience falls gemcitabine gene therapy humanized monoclonal antibodies improved inhibitor/antagonist innovation insight interest intravesical knowledge base knowledge translation literacy loss of function lung small cell carcinoma malignant breast neoplasm medically underserved member men minority health mortality neoplastic cell neurotoxic new technology news novel novel strategies older patient outreach outreach program p27 Cell Cycle Protein p27 Enzyme Inhibitor patient advocacy group pre-clinical pre-doctoral preclinical study prevent prognostic programs psychobiologic psychologic quantum racial and ethnic receptor research facility response statistics success taxane therapeutic target tissue resource tobacco prevention tool translational study tumor tumor growth tumor progression tumor xenograft underserved rural area

项目摘要

项目成果

COLIN P.N. DINNEY的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): The overall goal of this University of Texas M. D. Anderson Cancer Center Genitourinary SPORE in Bladder Cancer is to facilitate innovative translational research in the prevention, detection, and treatment of this disease leading to the elimination of bladder cancer as a major health problem. We have invested in several major translational research themes: identification of a novel class of genes referred to as "forerunners" whose involvement precedes the loss of function of major tumor suppressor genes in the development of cancer, identification of persons with an increased inherited and/or acquired risk of developing bladder cancer or recurring following therapy by molecular epidemiology, developing targeted bladder cancer therapies for advanced disease, and the development of improved therapy for superficial disease. To achieve these goals, our SPORE has assembled clinicians and basic scientists including urologists, medical oncologists, pathologists, molecular epidemiologists, molecular and cell biologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE includes 4 inter-related projects that deal with 1) early detection of bladder cancer, 2) risk assessment for bladder cancer 3) biology and therapeutic targeting of the epidermal growth factor receptor in bladder cancer, and 4) improving therapy for superficial bladder cancer through adenoviral mediated gene therapy. These projects are supported by 4 Cores: (A) Administrative; (B) Pathology & Tissue Resources; (C). Biostatistics and Bioinformatics; and (D) Clinical Trials and Data Management. All of the scientific projects are translational in nature; focus on human bladder cancer; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that is represented in each of the major projects. This SPORE addresses clinical dilemmas facing patients with all forms of bladder cancer, and will provide a critical component of a larger effort to develop effective strategies for chemoprevention, detection, molecular profiling and therapeutics, bioimmunotherapy, chemotherapy, supportive care, and community awareness. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of bladder cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文